Malikova I V
Antibiot Khimioter. 1989 Jan;34(1):52-6.
The study of antibacterial and chemotherapeutic activity of eremomycin, a novel glycopeptide antibiotic showed that it inhibited the growth of gram positive and acid fast microbes. The antibacterial spectrum of the novel glycopeptide was close to that of ristomycin and vancomycin. However, the in vitro antibacterial activity of eremomycin was 2-10 times higher than that of ristomycin and vancomycin. It also inhibited the growth of oxacillin resistant microbes at concentrations 5.20 times lower than those of vancomycin and ristomycin. By the therapeutic efficacy in albino mice with staphylococcal or streptococcal sepsis eremomycin was 2-4 times as superior as vancomycin and ristomycin and by the chemotherapeutic indices it was more than 10 times as superior.
新型糖肽类抗生素埃瑞霉素的抗菌及化疗活性研究表明，它能抑制革兰氏阳性菌和抗酸菌的生长。这种新型糖肽类抗生素的抗菌谱与瑞斯托霉素和万古霉素相近。然而，埃瑞霉素的体外抗菌活性比瑞斯托霉素和万古霉素高2至10倍。它还能在比万古霉素和瑞斯托霉素低5.20倍的浓度下抑制耐苯唑西林微生物的生长。在患有葡萄球菌或链球菌败血症的白化小鼠中，埃瑞霉素的治疗效果比万古霉素和瑞斯托霉素高2至4倍，其化疗指数比它们高10倍以上。
